Teladoc (NYSE: TDOC) executive sells shares and receives large equity awards

Rhea-AI Filing Summary

Teladoc Health, Inc. executive Kelly Bliss, President of U.S. Group Health, reported a mix of stock sales and equity awards. Bliss sold 26,647 shares of common stock in an open-market transaction at $5.117 per share to cover tax withholding obligations related to vesting equity awards, and held 84,747 common shares afterward.

On March 1, 2026, Bliss received a grant of 181,661 restricted stock units, each representing a contingent right to one Teladoc share, generally vesting one-third on the first anniversary of the grant date with the balance in eight quarterly installments. Around February 27, 2026, multiple restricted stock unit and performance stock unit awards were exercised or earned, including 27,458 performance stock units determined using metrics tied to Teladoc’s 2025 financial results, all converting to common stock on a one-for-one basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bliss Kelly

(Last) (First) (Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, SUITE 1700

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Group Health

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		M		3,488	A	(1)	63,542	D
Common Stock	02/27/2026		M		4,858	A	(1)	68,400	D
Common Stock	02/27/2026		M		36,610	A	(1)	105,010	D
Common Stock	02/27/2026		M		1,186	A	(2)	106,196	D
Common Stock	02/27/2026		M		5,198	A	(2)	111,394	D
Common Stock	03/02/2026		S		26,647(3)	D	$5.117	84,747	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/27/2026		M			3,488	(4)	(4)	Common Stock	3,488	$0	0	D
Restricted Stock Units	(1)	02/27/2026		M			4,858	(5)	(5)	Common Stock	4,858	$0	19,435	D
Restricted Stock Units	(1)	02/27/2026		M			36,610	(6)	(6)	Common Stock	36,610	$0	73,222	D
Performance Stock Units	(2)	02/27/2026		M			1,186	(7)	(7)	Common Stock	1,186	$0	0	D
Performance Stock Units	(8)	02/27/2026		A		27,458(9)		(10)	(10)	Common Stock	27,458	$0	27,458	D
Performance Stock Units	(2)	02/27/2026		M			5,198	(11)	(11)	Common Stock	5,198	$0	22,260	D
Restricted Stock Units	(12)	03/01/2026		A		181,661		(13)	(13)	Common Stock	181,661	$0	181,661	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.

3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.

4. On March 3, 2023, the reporting person was granted 41,853 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

5. On March 19, 2024, the reporting person was granted 58,300 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

6. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

7. On March 1, 2024, the reporting person earned 14,263 performance stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter.

8. Each performance stock unit represents a contingent right to receive one share of TDOC common stock.

9. Performance award amount determined based on metrics in respect of the issuer's 2025 financial results.

10. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

11. On March 1, 2026, the reporting person earned 27,458 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.

12. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.

13. One-third of the restricted stock units vest on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Kelly Bliss report in Teladoc (TDOC) Form 4?

Kelly Bliss reported one open-market sale of Teladoc common stock and multiple equity award activities. These included exercises and conversions of restricted stock units and performance stock units, as well as new grants that convert into TDOC common shares on a one-for-one basis over future vesting periods.

How many Teladoc (TDOC) shares did Kelly Bliss sell and at what price?

Kelly Bliss sold 26,647 shares of Teladoc common stock at a price of $5.117 per share. According to the disclosure, these shares were sold specifically to cover tax withholding obligations arising from the vesting of her restricted stock unit and performance stock unit awards.

What new equity awards did Kelly Bliss receive from Teladoc (TDOC)?

Kelly Bliss received 181,661 restricted stock units on March 1, 2026, each representing a contingent right to one Teladoc share. She also earned 27,458 performance stock units tied to 2025 financial metrics, which likewise convert into TDOC common stock on a one-for-one basis as they vest over time.

How do Kelly Bliss’s Teladoc (TDOC) restricted stock units and performance stock units vest?

Her restricted stock units generally vest one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments. Performance stock units vest one-third on March 1, 2026, with the balance also vesting in eight substantially equal quarterly installments thereafter.

How many Teladoc (TDOC) shares did Kelly Bliss hold after the reported sale?

After selling 26,647 Teladoc common shares, Kelly Bliss beneficially owned 84,747 common shares directly. This figure reflects her holdings following the open-market sale that was executed to satisfy tax withholding obligations related to vesting equity awards granted by Teladoc.

How are Teladoc (TDOC) restricted stock units and performance stock units converted for Kelly Bliss?

Each restricted stock unit and each performance stock unit converts into one share of Teladoc common stock. The conversion occurs as the awards vest according to their schedules, creating common share ownership for Kelly Bliss over time as performance conditions and service requirements are satisfied.